TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05007951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)
Description: injection volume of 0.5mL on days 0 and 28 (stage1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)
Description: injection volume of 0.5mL on days 0 and 28 (stage1)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1-S not less than 2.5 × 10^8 infectious units
Description: injection volume of 0.5mL on days 0 and 28 (stage1)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1-S not less than 2.5 × 10^8 infectious units
Description: injection volume of 0.5mL on days 0 and 28 (stage1)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)
Description: injection volume of 0.5mL on days 0 (stage2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)
Description: injection volume of 0.5mL on days 0 (stage2)
Study: NCT05970900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: 1. For patients with c-KIT exon 11 mutation, imatinib mesylate, 400mg, qd.~2. For patients with c-KIT exon 9 mutation, imatinib mesylate, 600mg or 800mg, qd.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local resection
Description: According to the characteristics of the location of the tumor, the surgeon decides the surgical approach based on the existing literature and the availability of surgical equipment, including:~1. Local transanal resection (TA)~2. Local resection transsacralapproach~3. Local resection via perineal approach~4. Local resection transvaginal approach
Study: NCT05505162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan
Description: Participants will receive two capsules of Zibotentan orally QD from day 6-19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/LNG
Description: Participants will receive two tablets of EE and LNG once on Day 1 and Day 15 as a combined oral dose.
Study: NCT05787873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIPS-2209-1
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIPS-2209-1
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIPS-2209-2, SIPS-2209-3
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIPS-2209-2, SIPS-2209-3
Description: QD, PO
Study: NCT05369104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Staphylococcus aureus Bacteriophages
Description: Single intra-articular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Anti-Staphylococcus aureus Bacteriophages
Description: Single intra-articular injection
Study: NCT05513937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Tablets administered orally once daily according instructions provided by Principal Investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Tablets administered orally once daily according instructions provided by Principal Investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
Study: NCT05039450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFX
Description: Investigational drug, Efruxifermin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFX
Description: Investigational drug, Efruxifermin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFX
Description: Investigational drug, Efruxifermin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05787080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: In the second hour of hemodialysis, vibration is applied to both calf muscles of the patients for 10 minutes three times a week for four weeks at low voltages.
Study: NCT04966377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS)
Description: Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS), increasing awareness of Syrian women under temporary protection against breast cancer, decreasing their perception of barriers to screening tests, developing early diagnosis behaviors (such as BSE, CBE and mammography), increasing their self-efficacy and breast cancer fears are expected to be reduced.
Study: NCT06042153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.25 mg; dose will gradually be increased every 4 weeks up to 1.0 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
Study: NCT06343948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Administration by intravenous bolus for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral administration for a cycle of 3 weeks.
Study: NCT06264882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: After first undergoing a pregnancy test, a clinician will administer an 80-mg subcutaneous injection of degarelix acetate (20 mg/mL; Ferring Pharmaceuticals Inc, Parsippany, NJ) to the women. A second injection will occur at 10 weeks. Compliance to the intervention will be ensured by having participants receive injections in the Clinical and Translational Research Center (CTRC), where all study visits will take place.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: After first undergoing a pregnancy test, a clinician will administer an 80-mg subcutaneous injection of degarelix acetate (20 mg/mL; Ferring Pharmaceuticals Inc, Parsippany, NJ) to the women. A second injection will occur at 10 weeks. Compliance to the intervention will be ensured by having participants receive injections in the Clinical and Translational Research Center (CTRC), where all study visits will take place.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Estradiol Patch
Description: Treatment will be a weekly transdermal patch (0.075 mg) administered in a double-blinded manner. This estradiol dose increases serum estradiol to \~90 pg/mL. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Placebo Patch
Description: Treatment will be a weekly transdermal patch (placebo inactive) administered in a double-blinded manner. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
Study: NCT04818736

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccination
Description: Dose 1: 0.5 mL at Day 0 Dose 2: 0.5 mL at Day 28

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants can receive the COVID-19 whenever they are eligible according to local provincial guidelines.
Study: NCT05771220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radial extracorporeal shockwave therapy+ evidence-based physical therapy
Description: The experimental group received six sessions of rESWT over six weeks in addition to an EBPT program. The rESWT procedure involved applying shockwaves to the affected area using a radial probe, with sessions lasting 10-15 minutes and consisting of up to 2000 impulses delivered at a frequency of 3-6 pulses per second and an energy intensity level of 1.8 bar, based on patient tolerance. Patients were seated or lying down during the rESWT procedure, with gel or oil applied to facilitate shockwave transmission through the skin. Additionally, participants received a 30-minute exercise program twice a week for 6 weeks, which included hot packs, stretching, range of motion exercises, and isometric shoulder and scapular exercises. They were also instructed to perform the same exercises at home daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham radial extracorporeal shockwave therapy+ evidence-based physical therapy
Description: The participants in the control group received six weeks of sham rESWT (radial extracorporeal shock wave therapy) combined with the EBPT (evidence-based physical therapy) program. The sham rESWT involved six sessions with a maximum of 200 impulses delivered at a low intensity, with the applicator placed on the affected area for the same duration as the experimental group. Additionally, participants received a 30-minute exercise program twice a week for 6 weeks, which included hot packs, stretching, range of motion exercises, and isometric shoulder and scapular exercises. They were also instructed to perform the same exercises at home daily.
Study: NCT04423874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold pressor task (CPT)
Description: The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance.~Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min.~The procedure is safe because the hand is removed before adverse effects can occur.~The participant will be given a break of 5 min in between trials, and will interchange hands between trials.~During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand. Each participant will complete no more than three trials (conditions) in a randomised order.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: index NOL
Description: Measurement of the index NOL™: Four sensors, placed non-invasively on one of the four participants' fingers, will make it possible to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playback Experiments
Description: During the experience, participants are led to listen, via headphones, to aversive non-verbal vocalizations (baby crying). The sound levels used to broadcast the non-verbal vocalisations will be scrupulously measured using approved and certified equipment during the preparation of the experiments. These sound volumes will be chosen so as not to inconvenience participants.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Video-pupillometry
Description: This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
Study: NCT04703673

Intervention type: DRUG
Intervention: Cineole
Description: self administration according to directions for use

Intervention type: DRUG
Intervention: Nasal Decongestant
Description: self administration according to directions for use
Study: NCT05132842

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete a Survey
Study: NCT05192356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(3)
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(3)
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO
Study: NCT05743738

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Doppler ultrasound
Description: Control venous Doppler ultrasound
Study: NCT06137924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic injection Bupivacaine plus dexamethasone
Description: The autonomic neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. Infiltration of 20 mL of non-diluted 0.5% bupivacaine plus dexamethasone 8 mg is performed at the celiac plexus and vagus nerve trajectory.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic injection bupivacainde plus dexamethasone plus a colloid
Description: bupivacaine plus dexamethasone 8 mg plus a colloid 10 cc (Gelofucin, B. Braun Medical S.A., Crissier, Suiza.) is performed at the celiac plexus and vagus nerve trajectory.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic injection bupivacaine plus clonidine
Description: bupivacaine 5% plus clonidine (0,150mgs) is performed at the celiac plexus and vagus nerve trajectory
Study: NCT06248281

Intervention type: OTHER
Intervention: combination of different rehabilitation strategies
Description: The psychoeducational program will be conducted through weekly online video-conferencing group sessions that will last for two hours. In addition to these sessions, participants will receive psychoeducational material such as readings, videos, podcasts, worksheets, and homework exercises every week. This material will allow participants to practice at their own pace during the session intervals.~The exercise training program for individuals with MS will be tailored to meet the unique and individual needs of each participant. To achieve this, a head and neck cooling protocol will be implemented using commercially available cooling equipment, specifically the Headcool Power and Neckcool Tie from Inuteq. Participants will need to wear the cooling cup and neck wrap for two hours daily. The equipment will be activated using 10°C tap water. Finally, a nutritionist will provide personalized nutritional guidance including weekly diet observation and recipe videos.

Intervention type: OTHER
Intervention: combination of different rehabilitation strategies
Description: The psychoeducational program will be conducted through weekly online video-conferencing group sessions that will last for two hours. In addition to these sessions, participants will receive psychoeducational material such as readings, videos, podcasts, worksheets, and homework exercises every week. This material will allow participants to practice at their own pace during the session intervals.~The exercise training program for individuals with MS will be tailored to meet the unique and individual needs of each participant. To achieve this, a head and neck cooling protocol will be implemented using commercially available cooling equipment, specifically the Headcool Power and Neckcool Tie from Inuteq. Participants will need to wear the cooling cup and neck wrap for two hours daily. The equipment will be activated using 10°C tap water. Finally, a nutritionist will provide personalized nutritional guidance including weekly diet observation and recipe videos.
Study: NCT05110703

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supergut
Description: Meal replacement shake

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary guidelines
Description: Dietary guidelines
Study: NCT05038020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKST4290
Description: Oral AKST4290

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo
Study: NCT05952245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBTI-based EMI
Description: Including brief iCBT-I for sleep support, stroke care education, and nurse-led real-time chat-based support messages, which were delivered according to participants' preferences (e.g., time and frequency).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education-based EMI
Description: Stroke and brief sleep hygiene education with chat-based support on the topics.
Study: NCT05156970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 or Carboplatin AUC5 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib 250mg qd for up to 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum)
Study: NCT05963789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical proprioceptive training
Description: Cervical proprioceptive training: The laser pointer will fixed on the highest point of the subject head with a band, patients sit upright on a chair and kept their head at the neutral position, while setting the laser light at the point on the wall in front of them. From this position, patients will be asked to flex, extend and rotate their head and then return to the neutral position. This training commenced with open eyes and then progress with closed eyes, tracing a pattern and standing position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional exercises
Description: Stretching posterior shoulder capsule Strengthening scapular muscles Shoulder stabilization PNF
Study: NCT05679128

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: identification of the cricothyroid membrane using Palpation
Description: identification of the cricothyroid using PALPATION, a procedure used to prepare for front of neck airway access

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Identification of the cricothyroid membrane using ultrasonography
Description: identification of the cricothyroid membrane, using ULTRASONOGRAPHY, a procedure used to prepare for front of neck airway access
Study: NCT05049096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: focused power ultrasound mediate inferior perirenal adipose tussue modification
Description: This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-control group
Description: participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
Study: NCT05617833

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MLT+EPO
Description: Melatonin component will be a single daily dose of 30 mg/kg enteral administered in the evening. EPO component is a two-stage regimen with high dose EPO (1000 U/kg/dose q 48 hrs ± 2hr IV) for 10 doses followed by maintenance dose EPO (400 U/kg/dose q Monday, Wednesday, Friday IV/SC) to 33-6/7wk. Maintenance EPO dosing will begin on the day closest to completing the high dose series.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo enteral and IV
Study: NCT05023356

Intervention type: DEVICE
Intervention: Non-contact vital signs monitoring with camera
Description: Monitor patients face image by non-contact vital signs monitoring with camera
Study: NCT05548348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib 160 mg, Q.D.
Description: Furmonertinib will be administered orally at a dose of 160 mg per time, Q.D.
Study: NCT06353828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD, synthetic form
Description: Cannabidiol enema

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo enema
Study: NCT05426889

Intervention type: PROCEDURE
Group type: OTHER
Intervention: subdural hematoma burr hole drainage
Description: For patients with larger hematoma, remove the hematoma by burr hole drainage

Intervention type: DRUG
Group type: OTHER
Intervention: drug conservative treatment
Description: The patient did not receive surgical treatment and chose conservative treatment
Study: NCT05073497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finger puppets
Description: In the experimental group, for distraction the researcher will put finger puppets consisting of various animal figures on his finger, and will ask the child to imitate these sounds by making animal-specific sounds that he moves with his finger. The researcher will also draw the child's attention to finger puppets by using methods such as making animals talk to each other and singing before and during venipuncture.
Study: NCT05290155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD7 CAR-T cells
Description: Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients
Study: NCT05002270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822 (KRAS G12C inhibitor)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822 (KRAS G12C inhibitor)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822 (KRAS G12C inhibitor)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab (EGFR inhibitor)
Description: Administered IV